Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Fauci, who has directed the National Institute of Allergy and Infectious Diseases since 1984, will step down in December.
An experimental vaccine produced an immune response to a range of different coronaviruses in mice and monkeys, including SARS-CoV-2.
Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
The quick spread of the BA.2 subvariant is likely due to its greater infectiousness rather than its ability to evade the immune system.
NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.
The benefits of achieving herd immunity thresholds have been less successful with respiratory viruses that continually mutate.
Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.
The HVTN 302 trial is evaluating experimental vaccines that deliver stabilized HIV spike proteins.
An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.
SARS-CoV-2 will probably continue to circulate indefinitely, and animal coronaviruses may emerge at any time.
New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.
The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.
The findings could have implications for vaccines against other rapidly evolving pathogens, such as influenza virus or SARS-CoV-2.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.